Darusentan Placebo

DRUG2 trials

Sponsors

Gilead Sciences

Conditions

Hypertension

Phase 3

DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension

CompletedNCT00330369

Gilead SciencesHypertension

Start: 2006-06-30End: 2009-01-31Updated: 2014-03-18

DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension

CompletedNCT00389779

Gilead SciencesHypertension

Start: 2006-09-30End: 2009-08-31Updated: 2014-03-18

Related Papers

A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial.

2009-09-11233 citations